Neuroprotective effects and mechanisms of the activation of group III metabotropic glutamate receptor in rodent models of Parkinson's disease
Current therapy for PD is focused on dopamine replacement by the use of L-DOPA and dopamine agonists, which relieve the Parkinsonian motor symptoms led by the degeneration of dopaminergic neurons in the substantia nigra par compacta (SNc). However, the long-term use of these agents could induce side...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
Imperial College London
2010
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.519273 |